Ari Melnick, MD - Cornell Medical College
Jane Skok, Ph.D. - New York University Medical School
03/02/2019 - Travel Forms - Travel Form( )
04/02/2019 - Abstracts
Estancia La Jolla Hotel and Spa
9700 North Torrey Pines Road
La Jolla, CA 92037
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
The precise and detailed 3D organization of chromosomal and chromatin looping is just now being understood to play a fundamental role in regulation of gene expression, DNA repair, DNA replication and cell cycle. Disruption of nuclear topology is a emerging as a potential new hallmark of cancer. For example somatic mutation of the loop and boundary protein CTCF are prevalent in many types of cancer, as are mutations of the various proteins that make up or regulate the cohesin complex that plays a central role in architectural effects. In addition there is rapidly increasing body of evidence that somatic mutation of looping elements can drive development of cancerby either disrupting the location of large gene enhancer clusters, boundary elements, lncRNAs that strengthen looping, and binding affinity of regulatory DNA elements for proteins that drive specific 3D architectural features.
Moreover it seems like master regulatory transcription factors may mark sites for preferential redistribution of 3D anchor points of various kinds. There are many new and fascinating observations coming out, novel mouse models, patient based observations. There is tremendous excitement currently about this new frontier in biology and its relation to cancer. I have chaired special lecture sessions on this for example at the AACR annual meeting and other venues. A conference on this new and very hot topic would be very impactful in disseminating ideas and creating new avenues of attack for understanding how nuclear topology drives normal and malignant biology, and perhaps generating some ideas on how the study of this novel field could lead to biomarkers and therapies for cancer patients.
|Eftychia Apostolou, PhD||Weill Cornell Medicine|
|Gerd A. Blobel, MD, PhD||University of Pennsylvania Pearlman School of Medicine|
|Wouter De Laat, PhD||Hubrecht Institute|
|Peter Fraser, PhD||Florida State University|
|Susana Hadjur,||University College London|
|Ross Levine, MD||Memorial Sloan Kettering Cancer Center|
|Mathieu Lupien, PhD||University of Toronto|
|Ari Melnick, MD||Cornell University|
|Leonid Mirny, PhD, M.Sc||Massachusetts Institute of Technology|
|Kim Nasmyth, PhD||Trinity College of Oxford University|
|Clodagh O'Shea, PhD||Salk Institute for Biological Studies|
|Tomi Pastan, MD, PhD||University of Missouri-Kansas City|
|Jan-Michael Peters,||Research Institute of Molecular Pathology|
|Jennifer E. Phillips-Cremins, PhD||University of Pennsylvania|
|Ana Pombo,||Max Delbruch Center for Molecular Medicine|
|Bing Ren, PhD||Ludwig Cancer Research|
|Benjamin Rowland,||Netherlands Cancer Institute|
|Peter Scacheri, PhD||Case Western Reserve University|
|Jane Skok, PhD||NYU Langone Health|
|Francois Spitz,||Pasteur Institute|
San Diego International Airport (SAN) is approximately 30 minutes from the meeting location.
International participants are welcome to arrive on Wednesday to minimize chances for missed or delayed connections.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.